2 ASX healthcare shares outperforming on big news

These two ASX healthcare shares are on the way up on Tuesday after positive news announcements.

| More on:
Shot of two young scientists using a laptop in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX healthcare shares are in the red on Tuesday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) down 0.46% and the S&P/ASX 200 Index (ASX: XJO) down 0.96% in early trading.

As always, there are outliers, and these two ASX healthcare shares are outperforming today.

Let's find out why.

Race Oncology Ltd (ASX: RAC)

Race Oncology shares are 2.18% higher at $1.64 apiece after the biotech reported positive progress in its Phase 2 trial of Bisantrene for the treatment of relapsed or refractory acute myeloid leukaemia (AML).

The clinical-stage biopharmaceutical company is investigating a small-molecule chemotherapeutic drug called bisantrene in the treatment of cancer.

The ASX healthcare share is in the green on news that investigators at the Sheba Medical Centre in Israel have successfully concluded the Phase 1b/2 trial of RC110 bisantrene, which met the predetermined efficacy criteria.

In a statement, Race Oncology said 40% of patients with highly advanced disease showed a response to the bisantrene combination treatment. Five patients had complete responses, and one had a partial response. This surpassed the trial's predefined efficacy goal of at least three complete responses.

Race said the trial results strongly supported the company's intention to initiate a new Phase 1/2 investigator-sponsored AML trial using the reformulated version of bisantrene, called RC220.

The ASX healthcare share is currently up 92.95% in the year to date and 34.43% over the past 12 months.

Alcidion Group Ltd (ASX: ALC)

Alcidion Group shares are up 2.56% to 8 cents per share on Tuesday. This follows the technology solutions developer releasing its quarterly activities report this morning.

Investors in this ASX healthcare share appear to be pleased with the numbers on Tuesday.

Alcidion reported record quarterly cash receipts of $18.6 million in 4Q FY24. That's up from $17.6M in the prior corresponding period (pcp).

The company said it was also seeing the impact of cost-saving initiatives. Staff costs in 4Q were $6.3 million, down significantly from $8.1 million pcp.

Alcidion said it expected unaudited FY24 revenue to be in the range of $37 million to $37.5 million. Approximately 74% of that is annual recurring revenue (ARR) and 26% is services revenue.

Alcidion Group Managing Director Kate Quirke said:

Q4 was a strong period for cash collections with record cash receipts of $18.6M resulting in a positive cashflow for the quarter and the second half of the year.

As indicated at the time of our half year results, we expected to deliver a strong second half cashflow result which now positions us well as we head into the new financial year.

The ASX healthcare share is down 1.25% in the year to date and down 39.23% over the past 12 months.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Alcidion Group. The Motley Fool Australia has recommended Alcidion Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »